Financial Performance - Operating revenue increased by 22.75% to CNY 3,067,936,076.77 year-on-year[12] - Net profit attributable to shareholders was CNY 125,722,878.43, a significant recovery from a loss of CNY 71,410,895.85 in the same period last year[12] - Basic earnings per share improved to CNY 0.122 from a loss of CNY 0.074 in the same period last year[12] - The company's net profit for Q1 2021 was CNY 187,817,286.10, a significant increase compared to CNY 51,070,646.08 in Q1 2020, representing a growth of approximately 267%[54] - The company's operating profit for Q1 2021 was CNY 19,063,827.71, compared to a loss of CNY 33,712,684.83 in Q1 2020, marking a turnaround in performance[60] - The total comprehensive income for Q1 2021 was CNY 172,788,720.40, significantly higher than CNY 46,100,965.75 in Q1 2020[56] Cash Flow - Net cash flow from operating activities decreased by 56.05% to CNY 230,216,190.84 compared to the previous year[12] - The net cash flow from operating activities for Q1 2021 was CNY 230.22 million, a significant decrease of 56% compared to CNY 523.83 million in Q1 2020[62] - The total cash inflow from investment activities in Q1 2021 was CNY 512.21 million, down from CNY 1.12 billion in Q1 2020, indicating a decline of approximately 54%[64] - The cash outflow from investment activities in Q1 2021 was CNY 1.64 billion, compared to CNY 1.18 billion in Q1 2020, marking an increase of about 39%[64] - The net cash flow from financing activities in Q1 2021 was negative at CNY -144.62 million, contrasting with a positive net cash flow of CNY 114.23 million in Q1 2020[64] Assets and Liabilities - Total assets decreased by 4.52% to CNY 19,917,600,707.04 compared to the end of the previous year[12] - The total liabilities of the company as of March 31, 2021, were RMB 12,892,404,133.62, compared to RMB 12,603,176,219.43 in the previous year[42] - The company's total current assets amounted to RMB 6,331,214,506.41, a decrease from RMB 7,347,865,196.02 as of December 31, 2020[39] - The company's non-current assets totaled RMB 13,586,386,200.63, slightly up from RMB 13,511,906,988.10 year-over-year[39] - Total liabilities as of March 31, 2021, were ¥6,914,268,439.04, an increase from ¥5,739,582,425.87 at the end of 2020, representing a rise of 20.5%[50] Shareholder Information - The total number of shareholders at the end of the reporting period was 55,439[19] - Zhejiang Haizheng Group Co., Ltd. held 27.44% of the shares, making it the largest shareholder[19] Investment and Financing Activities - The company issued convertible bonds to HPPC, resulting in a new debt of ¥1,389,014,820.22[23] - The company plans to issue short-term financing bonds totaling up to RMB 2 billion, with a maturity of no more than 9 months, to be issued in tranches over the next two years[31] - Long-term borrowings increased by 34.86% to ¥1,466,910,059.73 due to new medium and long-term financing[23] Operational Costs and Expenses - Operating costs rose by 32.00% to ¥1,850,568,517.11 driven by increased sales[23] - The company reported a decrease in sales expenses to CNY 197,695,112.45 in Q1 2021 from CNY 313,572,623.39 in Q1 2020, a reduction of approximately 37%[56] - The financial expenses for Q1 2021 were CNY 44,606,002.67, an increase from CNY 38,079,814.62 in Q1 2020, representing an increase of about 17%[60] Market and Product Development - The company has not disclosed any new product developments or market expansion strategies in this report[12] - The company plans to continue expanding its market presence and investing in new technologies and products[50]
海正药业(600267) - 2021 Q1 - 季度财报